Diana Barb

5.7k total citations · 5 hit papers
31 papers, 3.5k citations indexed

About

Diana Barb is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Diana Barb has authored 31 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Epidemiology, 16 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Surgery. Recurrent topics in Diana Barb's work include Liver Disease Diagnosis and Treatment (17 papers), Diet, Metabolism, and Disease (6 papers) and Liver Disease and Transplantation (5 papers). Diana Barb is often cited by papers focused on Liver Disease Diagnosis and Treatment (17 papers), Diet, Metabolism, and Disease (6 papers) and Liver Disease and Transplantation (5 papers). Diana Barb collaborates with scholars based in United States, Australia and Denmark. Diana Barb's co-authors include Mary E. Rinella, Kenneth Cusi, Manal F. Abdelmalek, Brent A. Neuschwander‐Tetri, Rohit Loomba, Mohammad Shadab Siddiqui, David E. Kleiner, Stephen H. Caldwell, Christos S. Mantzoros and Anke Neuwirth and has published in prestigious journals such as PLoS ONE, American Journal of Clinical Nutrition and Hepatology.

In The Last Decade

Diana Barb

29 papers receiving 3.4k citations

Hit Papers

AASLD Practice Guidance on the clinical ass... 2020 2026 2022 2024 2023 2022 2020 2025 2025 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
    2023 1.2k citations Mary E. Rinella, Manal F. Abdelmalek et al. profile →
  2. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
    2022 592 citations Kenneth Cusi, Scott Isaacs et al. Endocrine Practice profile →
  3. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
    2020 231 citations Romina Lomonaco, Eddison Godinez Leiva et al. Diabetes Care profile →
  4. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
    2025 32 citations Diana Barb, Srilaxmi Kalavalapalli et al. Journal of Hepatology profile →
  5. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
    2025 25 citations Kenneth Cusi, Manal F. Abdelmalek et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diana Barb United States 20 2.8k 1.5k 938 627 536 31 3.5k
Carol Sargeant United States 12 3.5k 1.3× 1.7k 1.1× 1.5k 1.6× 435 0.7× 851 1.6× 17 4.2k
Luis Calzadilla Bertot Australia 16 3.2k 1.1× 1.5k 1.0× 1.6k 1.7× 505 0.8× 564 1.1× 38 3.6k
Romina Lomonaco United States 25 3.6k 1.3× 2.2k 1.5× 1.1k 1.2× 657 1.0× 734 1.4× 37 4.2k
Goh Eun Chung South Korea 28 1.7k 0.6× 744 0.5× 932 1.0× 341 0.5× 674 1.3× 137 3.0k
Manirath Srishord United States 13 3.6k 1.3× 1.8k 1.2× 1.6k 1.7× 417 0.7× 606 1.1× 28 4.0k
Fabio Nascimbeni Italy 28 4.1k 1.5× 2.2k 1.5× 1.5k 1.6× 639 1.0× 563 1.1× 54 4.8k
Aynur Ünalp United States 17 4.1k 1.5× 2.1k 1.4× 1.7k 1.8× 526 0.8× 673 1.3× 32 4.6k
Eduardo Vilar‐Gómez United States 26 3.9k 1.4× 1.8k 1.2× 1.9k 2.1× 630 1.0× 647 1.2× 76 4.3k
Beverly Orsak United States 16 2.8k 1.0× 1.8k 1.2× 905 1.0× 511 0.8× 556 1.0× 20 3.2k
Samer Gawrieh United States 26 2.0k 0.7× 762 0.5× 995 1.1× 288 0.5× 335 0.6× 106 2.5k

Countries citing papers authored by Diana Barb

Since Specialization
Citations

This map shows the geographic impact of Diana Barb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Barb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Barb more than expected).

Fields of papers citing papers by Diana Barb

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Barb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Barb. The network helps show where Diana Barb may publish in the future.

Co-authorship network of co-authors of Diana Barb

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Barb. A scholar is included among the top collaborators of Diana Barb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Barb. Diana Barb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barb, Diana, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.. (2025). Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of Hepatology. 82(6). 979–991. 32 indexed citations breakdown →
2.
Cusi, Kenneth, Manal F. Abdelmalek, Caroline M. Apovian, et al.. (2025). Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 48(7). 1057–1082. 25 indexed citations breakdown →
3.
Valderrábano, Rodrigo J., et al.. (2022). Body Fat Distribution in Lean Individuals with Metabolic Abnormalities. Metabolic Syndrome and Related Disorders. 21(2). 79–84. 3 indexed citations
4.
Cusi, Kenneth, Scott Isaacs, Diana Barb, et al.. (2022). American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocrine Practice. 28(5). 528–562. 592 indexed citations breakdown →
5.
Gastaldelli, Amalia, Silvia Sabatini, Fabrizia Carli, et al.. (2021). PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver International. 41(11). 2659–2670. 74 indexed citations
6.
7.
Bril, Fernando, et al.. (2021). Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. PLoS ONE. 16(6). e0251449–e0251449. 12 indexed citations
8.
Alzghoul, Bashar, Diana Barb, Mamoun Mardini, et al.. (2021). Prevalence and characteristics of self-reported hypothyroidism and its association with nonorgan-specific manifestations in US sarcoidosis patients: a nationwide registry study. ERJ Open Research. 7(1). 754–2020. 9 indexed citations
9.
Bril, Fernando, Michael J. McPhaul, Srilaxmi Kalavalapalli, et al.. (2021). Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes. The Journal of Clinical Endocrinology & Metabolism. 106(11). e4360–e4371. 11 indexed citations
10.
Lomonaco, Romina, Eddison Godinez Leiva, Fernando Bril, et al.. (2020). Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care. 44(2). 399–406. 231 indexed citations breakdown →
11.
Lomonaco, Romina, Nada Fanous, Srilaxmi Kalavalapalli, et al.. (2020). 1461-P: Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD). Diabetes. 69(Supplement_1). 1 indexed citations
12.
Bril, Fernando, Diana Julie Leeming, M.A. Karsdal, et al.. (2019). Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. Diabetes Care. 42(7). 1348–1351. 42 indexed citations
13.
Barb, Diana, et al.. (2019). Profound Hypoglycemia in a Hospitalized Patient: Paraneoplastic Insulin-Like Growth Factor. The American Journal of Medicine. 132(12). 1414–1416.
14.
Bril, Fernando, Diana Barb, Romina Lomonaco, Jinping Lai, & Kenneth Cusi. (2019). Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. Journal of Hepatology. 72(3). 401–410. 42 indexed citations
15.
Cusi, Kenneth, Fernando Bril, Diana Barb, et al.. (2018). Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 21(4). 812–821. 137 indexed citations
16.
Rhee, Mary K., Sandra E. Safo, Sandra L. Jackson, et al.. (2017). Inpatient Glucose Values: Determining the Nondiabetic Range and Use in Identifying Patients at High Risk for Diabetes. The American Journal of Medicine. 131(4). 443.e11–443.e24. 2 indexed citations
17.
Barb, Diana, Paola Portillo-Sánchez, & Kenneth Cusi. (2016). Pharmacological management of nonalcoholic fatty liver disease. Metabolism. 65(8). 1183–1195. 90 indexed citations
18.
Olson, Darin E., Zhu Ming, Qi Long, et al.. (2015). Increased Cardiovascular Disease, Resource Use, and Costs Before the Clinical Diagnosis of Diabetes in Veterans in the Southeastern U.S.. Journal of General Internal Medicine. 30(6). 749–757. 11 indexed citations
19.
Barb, Diana, Catherine J. Williams, Anke Neuwirth, & Christos S. Mantzoros. (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. American Journal of Clinical Nutrition. 86(3). 858S–866S. 275 indexed citations
20.
Barb, Diana, et al.. (2007). Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway. Endocrine Related Cancer. 14(4). 995–1005. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carol Sargeant Breakdown of academic impact, for papers by Luis Calzadilla Bertot Breakdown of academic impact, for papers by Romina Lomonaco Breakdown of academic impact, for papers by Goh Eun Chung Breakdown of academic impact, for papers by Manirath Srishord Breakdown of academic impact, for papers by Fabio Nascimbeni Breakdown of academic impact, for papers by Aynur Ünalp Breakdown of academic impact, for papers by Eduardo Vilar‐Gómez Breakdown of academic impact, for papers by Beverly Orsak Breakdown of academic impact, for papers by Samer Gawrieh
Rankless by CCL
2026